Bio
As General Counsel & Vice President Business Development at the Institute for OneWorld Health, Julie oversees all of OneWorld Health’s legal matters and is responsible for business development including setting up and maintaining key partnerships among OneWorld Health, academia and pharmaceutical companies in different disease areas. Prior to joining OneWorld Health she spent almost seven years with Bayer HealthCare, most recently as Assistant General Counsel for the Biological Products Division. A primary focus of her practice has been international intellectual property and related matters. Julie is active with the National Asian Pacific American Bar Association (NAPABA), and has been a member of the ABA Special Committee on Bioethics and the Law. Julie received her BA in Chemistry from Reed College and her JD from Franklin Pierce Law Center.

Talk Description
An Alternative Partnership Paradigm: Malaria Case Study
The Institute for OneWorld Health (iOWH) develops safe, effective and affordable new medicines for people with infectious diseases in the developing world. iOWH works with partners across sectors to make such medicines available. This talk will focus on the Artemisinin Project, a partnership among iOWH, UC Berkeley, Amyris and sanofi-aventis. This project’s goal is to create a complementary source of non-seasonal, high-quality and affordable artemisinin to supplement the current supply. Artemisinin is a key starting material to ACTs, recommended as first-line therapy for treatment of malaria.